Thus, in line with several classical immune checkpoints (PD-1/PD-L1 and CTLA-4), the blockage of the CD73-adenosine axis has been considered a grand promise for further improving clinical outcomes in cancer patients [49,50]. This evidence concerns the gene NT5E and cancer.